




RealRate

PHARMACEUTICAL 2017

Histogen Inc.
Rank 129 of 313



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai



PHARMACEUTICAL 2017

Histogen Inc.
Rank 129 of 313



The relative strengths and weaknesses of Histogen Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Histogen Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 188% points. The greatest weakness of Histogen Inc. is the variable Revenues, reducing the Economic Capital Ratio by 44% points.

The company's Economic Capital Ratio, given in the ranking table, is -121%, being 296% points above the market average of -417%.

Input Variable	Value in 1000 USD
Assets, Current	80,453
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	39,560
Liabilities, Non-Current	0
Other Assets	1,610
Other Compr. Net Income	-2.2
Other Expenses	0
Other Liabilities	0
Other Net Income	98
Property and Equipment	261
Research and Development	20,294
Revenues	799
Selling, General and Administrative Expense	10,337

Output Variable	Value in 1000 USD
Assets	82,324
Liabilities	39,560
Expenses	30,631
Stockholders Equity	42,764
Net Income	-29,733
Comprehensive Net Income	-29,735
Economic Capital Ratio	-121%

